Toward the development of mRNA-LNP vaccines with reduced adverse reactions

Abstract

Messenger RNA vaccines based on lipid nanoparticles (mRNA-LNPs) are promising vaccine modalities. However, some mRNA-LNP vaccines frequently cause adverse reactions, including local symptoms such as swelling and pain, and general symptoms such as fever. Therefore, developing mRNA-LNP vaccines with fewer adverse reactions is required. In this presentation, I will introduce our findings on the mechanism of mRNA-LNP vaccine induction of adverse reactions and the mRNA-LNP vaccine project to reduce adverse reactions.